Autoimmune Disorders in Heart Failure With Preserved Ejection Fraction (JACC Heart Failure July 2024)-Article: Autoimmune Disorders in Heart Failure With Preserved Ejection Fraction

Article: Autoimmune Disorders in Heart Failure With Preserved Ejection Fraction

Pdf Summary

The document discusses a study that explored the impact of autoimmune and inflammatory disorders on patients with heart failure with preserved ejection fraction (HFpEF). Around 8% of HFpEF patients had autoimmune disorders, with rheumatoid arthritis and lupus being common. These patients were mostly women and showed certain differences like higher heart rates and poorer oxygen transport in muscles. Though their hemodynamics were similar at rest and during exercise, they had increased risk of adverse outcomes, particularly heart failure hospitalization. Tailored treatment strategies are suggested for this subgroup due to their unique characteristics. The document also mentions the potential benefits of anti-inflammatory therapies in improving outcomes for HFpEF patients with inflammatory conditions. It further discusses ongoing trials testing IL-6 inhibitors and myeloperoxidase inhibitors in HFpEF treatment. The importance of understanding ventilatory efficiency and exercise intolerance in heart failure patients is emphasized, along with the need for more research on the impact of inflammatory diseases on these parameters. Overall, the study sheds light on the complexities of managing HFpEF in the presence of autoimmune and inflammatory disorders and suggests potential therapeutic approaches to enhance patient outcomes.

Keywords

autoimmune disorders

inflammatory disorders

heart failure with preserved ejection fraction

rheumatoid arthritis

lupus

hemodynamics

heart failure hospitalization

anti-inflammatory therapies

IL-6 inhibitors

myeloperoxidase inhibitors